New hope for lung cancer patients when disease morphs into more aggressive form
NCT ID NCT07001995
Summary
This study is testing a new combination of drugs for people with a specific type of lung cancer. It's for patients whose non-small cell lung cancer has changed into a more aggressive small-cell type after their first treatment stopped working. The trial will see if adding a new targeted drug (limertinib) to standard chemotherapy can better control the cancer and is safe for about 30 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yongchang Zhang
Changsha, Hunan, 410013, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.